Iqvia Holdings Inc. (IQV) Stock Price & Analysis
Iqvia Holdings Inc. (IQV) rose 1.39% to USD 186.25 as of June 9, 2026 at 22:40 UTC, according to Nexqual real-time market data.
IQV last closed at USD 183.69; the session ranged USD 183.64–190.68 on volume of 1,131,164 shares. Market capitalization is $31.09B, with a 52-week range of USD 153.01–247.05 (NYQ). Source: Nexqual, June 9, 2026 at 22:40 UTC.
Key Statistics (as of June 9, 2026 at 22:40 UTC)
| Price | USD 186.25 |
|---|---|
| Change | ▲ 1.39% (up) |
| Previous Close | USD 183.69 |
| Open | USD 185.22 |
| Day Range | USD 183.64 – 190.68 |
| 52-Week Range | USD 153.01 – 247.05 |
| Volume | 1,131,164 shares |
| Market Cap | $31.09B |
| Exchange | NYQ |
Technical Analysis (IQV)
Nexqual's technical model rates IQV "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 22:40 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 59.16 (neutral) |
| vs SMA50 | Above (USD 172.37) |
| MACD | 3.98 (positive) |
Analyst Ratings (IQV)
Wall Street analysts rate IQV "Strong Buy" based on 20 analysts, with a mean price target of USD 228.1 (range USD 195–287), per Nexqual as of June 9, 2026 at 22:40 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 20 |
| Mean Target | USD 228.1 |
| High Target | USD 287 |
| Low Target | USD 195 |
| Buy / Hold / Sell | 21 / 2 / 0 |
Earnings (IQV)
| Next Earnings Date | 2026-07-21 |
|---|---|
| EPS Estimate | USD 3.03 |
| Revenue Estimate | $4.31B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.9 vs est 2.82 ▲ beat |
| 2025-12-31 | USD 3.42 vs est 3.4 ▲ beat |
| 2025-09-30 | USD 3 vs est 2.98 ▲ beat |
| 2025-06-30 | USD 2.81 vs est 2.77 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:40 UTC.
Financials & Fundamentals (IQV)
| Total Revenue | $16.63B |
|---|---|
| Revenue Growth (YoY) | +8.40% |
| Gross Margin | +32.99% |
| Operating Margin | +13.61% |
| Profit Margin | +8.33% |
| ROE | +22.49% |
| Debt / Equity | 255.43 |
| Current Ratio | 0.75 |
| Total Cash | $2.10B |
| Total Debt | $16.22B |
| Free Cash Flow | $2.16B |
Source: Nexqual, June 9, 2026 at 22:40 UTC.
Financial Health Score (IQV)
Nexqual rates Iqvia Holdings Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 22:40 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 33%, operating 14% |
| Balance Sheet | Critical — $2.10B cash vs $16.2B debt |
| Cash Flow | Solid — FCF $2.16B, 13% margin |
| Efficiency | Strong — ROE 22%, ROA 5.1% |
Ownership (IQV)
| Insider Ownership | +1.08% |
|---|---|
| Institutional Ownership | +103.53% |
| Shares Outstanding | 166.90M |
| Float | 158.55M |
| Short % of Float | +3.42% |
Source: Nexqual, June 9, 2026 at 22:40 UTC.
Leadership (IQV)
Iqvia Holdings Inc. is led by Ari Bousbib (age 64), CEO & Chairman, per Nexqual as of June 9, 2026 at 22:40 UTC.
| CEO & Chairman | Ari Bousbib (age 64) |
|---|---|
| President of Research & Development Solutions | W. Richard Staub (age 62) |
| President of Commercial Solutions | Alistair Grenfell (age 51) |
| Executive VP & Chief Financial Officer | Michael J. Fedock (age 49) |
| Executive Vice President of Global Infrastructure & Operations | James G. Berkshire (age 51) |
Major Backers & Investors (IQV)
Notable institutional backers of Iqvia Holdings Inc. include Harris Associates L.P., JPMorgan, Artisan Partners Limited Partnership, according to Nexqual as of June 9, 2026 at 22:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Harris Associates L.P. | 10.32% |
| JPMorgan | 3.24% |
| Artisan Partners Limited Partnership | 3.03% |
| Boston Partners | 2.54% |
| Invesco | 1.95% |
| Fidelity | 1.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.04% |
| BlackRock | 10.31% |
| State Street | 5.7% |
| Geode Capital | 2.67% |
Source: Nexqual, June 9, 2026 at 22:40 UTC.
From Iqvia Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Our scaled and growing information set contains approximately 68 petabytes of unique proprietary data sourced from approximately 150,000 data suppliers and covering over one million data feeds globally.
- We combine our proprietary information assets with advanced analytics, transformative technology and domain expertise to develop clinical and commercial capabilities that enable us to grow our relationships with healthcare stakeholders throughout the life science's value chain.
- Second, the addressable opportunity for connected healthcare is approximately $55 billion, and includes areas such as revenue cycle management, payer & provider analytics and clinical decision support services. • Technology enabled commercial operations: Total addressable market of approximately $84 billion in 2025 that includes information, data warehousing, IT outsourcing, software applications and other services in the broader market for IT services.
- Beyond our proprietary information assets, we have developed key capabilities to assess opportunities to develop and commercialize therapies, support and defend the value of medicines and help our clients operate more efficiently through the application of our clinical, scientific and operational knowledge as well as our insight-driven decision-making and cost-efficient technology solutions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MTD | Mettler-Toledo International, I | USD 1,162.79 | ▲ 0.73% |
| FTV | Fortive Corporation | USD 62.78 | ▲ 2.45% |
| COO | The Cooper Companies, Inc. | USD 68.62 | ▲ 1.9% |
| TFX | Teleflex Incorporated | USD 135.75 | ▲ 4.55% |
| CRL | Charles River Laboratories Inte | USD 189.85 | ▲ 4.69% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:40 UTC. This page is informational and not investment advice.